Heat Biologics Inc. said it saw positive interim data of its Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's Opdivo nivolumab in advanced non-small cell lung cancer.
The company's HS-110 is an "off-the-shelf" allogeneic cell-based therapy designed to activate patients' immune system against multiple cancer testis antigens to elicit a diverse and robust immune response against tumor cells.
Heat Biologics said substantial survival benefit was observed in a cohort of previously treated, checkpoint inhibitor naive patients with advanced non-small cell lung cancer.
A median progression free survival of 1.8 months and a median overall survival of 24.6 months was observed with a median follow-up time of 19.4 months. The one-year survival rate of cohort A is 61.7%.
For NSCLC patients who had previously been treated with a checkpoint inhibitor and whose disease had subsequently progressed, a median progression free survival of 2.8 months and median overall survival of 11.9 months was observed with a median follow-up time of 11.9 months.
The company said 30% of the patients in Cohort A and 26% of the patients in Cohort B are still alive. HS-110 has a favorable safety profile and has been administered in 200 patients to date. There have been no treatment-related serious adverse reactions. A review of immune-related adverse events reported in the study raised no safety concerns.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.